Drug intelligence / Profile preview

Dunaliella bardawil

Development stage
Phase 3
Lead developer
Sheba Medical Center
Modality
Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
Administration
Oral, Topical
01

Overview

Dunaliella bardawil is a powder derived from a species of microalga, which serves as a natural source of carotenoids. It is particularly rich in 9-cis β-carotene, containing an approximate 1:1 ratio of 9-cis and all-trans β-carotene. The 9-cis β-carotene is a precursor to 9-cis retinoic acid, a ligand that can activate both Retinoic Acid Receptors (RARs) and Retinoid X Receptors (RXRs), thus modulating gene expression. Clinical investigations have explored its use as an oral dietary supplement for mild, chronic, plaque-type psoriasis, where it demonstrated efficacy in improving skin lesions without the liver and lipid-related side effects associated with synthetic retinoids. It has also been studied for its potential to raise HDL-cholesterol levels and inhibit atherogenesis. The research was supported by Nikken Sohonsha Corporation and conducted at Sheba Medical Center.

Other names
Dunaliella bardawil powder
02

Targets

PPARA (Peroxisome proliferator-activated receptor alpha)RAR (Retinoic acid receptor)RXRA (Retinoid X receptor alpha)

Beyond the preview

Go deeper on Dunaliella bardawil.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Dunaliella bardawil.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call